128 related articles for article (PubMed ID: 10789875)
1. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels.
Fitzgerald PB; Kapur S; Remington G; Roy P; Zipursky RB
Psychopharmacology (Berl); 2000 Mar; 149(1):1-5. PubMed ID: 10789875
[TBL] [Abstract][Full Text] [Related]
2. Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade.
Fitzgerald PB; Kapur S; Caligiuri MP; Jones C; Silvestri S; Remington G; Zipursky RB
Neuropsychopharmacology; 2000 Jan; 22(1):19-26. PubMed ID: 10633487
[TBL] [Abstract][Full Text] [Related]
3. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man.
Nyberg S; Nordström AL; Halldin C; Farde L
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():81-5. PubMed ID: 8866769
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
6. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients.
Nyberg S; Farde L; Halldin C
Psychiatry Res; 1996 Oct; 67(3):163-71. PubMed ID: 8912956
[TBL] [Abstract][Full Text] [Related]
7. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study.
Kapur S; Zipursky R; Roy P; Jones C; Remington G; Reed K; Houle S
Psychopharmacology (Berl); 1997 May; 131(2):148-52. PubMed ID: 9201802
[TBL] [Abstract][Full Text] [Related]
8. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
Nordström AL; Farde L; Wiesel FA; Forslund K; Pauli S; Halldin C; Uppfeldt G
Biol Psychiatry; 1993 Feb; 33(4):227-35. PubMed ID: 8097114
[TBL] [Abstract][Full Text] [Related]
9. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
[TBL] [Abstract][Full Text] [Related]
10. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
Nyberg S; Farde L; Halldin C
Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
[TBL] [Abstract][Full Text] [Related]
12. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
13. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
[TBL] [Abstract][Full Text] [Related]
14. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
[TBL] [Abstract][Full Text] [Related]
15. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
[TBL] [Abstract][Full Text] [Related]
16. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457.
Talvik M; Nordström AL; Nyberg S; Olsson H; Halldin C; Farde L
Am J Psychiatry; 2001 Jun; 158(6):926-30. PubMed ID: 11384901
[TBL] [Abstract][Full Text] [Related]
17. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
[TBL] [Abstract][Full Text] [Related]
18. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
[TBL] [Abstract][Full Text] [Related]
20. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
